4.06 0.00 (0.00%)
Pre-Market: 8:23AM EDT
|Bid||4.15 x 100|
|Ask||4.17 x 1000|
|Day's Range||3.75 - 4.38|
|52 Week Range||2.14 - 4.71|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 30, 2018 - May 4, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.78|
SOUTH SAN FRANCISCO, Calif. , April 19, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the pricing of its previously announced underwritten public offering of 16,000,000 ...
SOUTH SAN FRANCISCO, Calif., April 18, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today announced that it intends to offer and sell up to 15,000,000 shares of its common stock in an underwritten public offering. Rigel expects to grant the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of common stock sold in the public offering on the same terms and conditions. All of the shares to be sold in the offering are to be sold by Rigel, with the proceeds to be used for activities in connection with the commercial launch of TAVALISSE in the United States, research and development and general corporate purposes.
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL ) announced Tuesday the approval of its Tavalisse for chronic immune thrombocytopenia — an achievement prompting a 14-percent pop in its stock price. Analysts ...
Pricing and the wear and tear of years of clinical trials remain issues for the drug-development industry.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL ) stock ...
NEW YORK, NY / ACCESSWIRE / April 18, 2018 / Medical stocks Intuitive Surgical and Rigel Pharmaceuticals both saw big gains on Tuesday. Intuitive plowed ahead after crushing first quarter earnings estimates ...
Rigel Pharmaceuticals Inc. said Tuesday afternoon that the drug that has been the company's main focus has been approved by the Food and Drug Administration. The company last week posted a press release ...
SOUTH SAN FRANCISCO, Calif., April 17, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today announced that the U.S. Food and Drug Administration (FDA) approved TAVALISSE™ (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
The U.S. Food and Drug Administration on Tuesday approved Rigel Pharmaceuticals Inc's treatment for a rare bleeding disorder. Rigel's Tavalisse was approved https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=report.page ...
It was a busy week last week in the biotechnology space, with a whole host of companies putting out updates on their respective operations (primarily rooted in development pipelines) and these updates subsequently injecting a considerable amount of volatility into the markets on their release. Here’s a look at some of the biggest movers, what […] The post Here’s What Happened Last Week In Biotech appeared first on Market Exclusive.
Winning FDA approval of a rare disease drug for children would net the company a voucher, which it could use to accelerate FDA review of another drug or sell to the highest bidder for millions of dollars.
Below is a list of notable corporate events for the week beginning April 16. Note, this list is not comprehensive and all dates are subject to change. All times are ET. Monday Notable Earnings Netflix, ...
NEW YORK, NY / ACCESSWIRE / April 13, 2018 / Rigel shares were popping on Thursday but unfortunately it was due to a mistake. The company corrected the mistake after-hours and announced that there had ...
Rigel Pharmaceuticals Inc. stock roared more than 16% higher Thursday, but the potential catalyst for that move was a mistake, the company said after markets closed Thursday. Rigel said that information ...
SOUTH SAN FRANCISCO, Calif. , April 12, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), reported that due to an error by the external host of its investor relations website, inaccurate ...
Rigel's (RIGL) stock plunges 13% on the failure of a phase II study on lead drug, fostamatinib, in patients with IgA nephropathy (IgAN).
As far as two analysts are concerned, the path to unlocking big biotech catalysts looks promising for two companies: Scpharmaceuticals Inc (NASDAQ:SCPH) and Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). As anticipation soars around lead indications up for FDA assessment within a matter of weeks and months, analysts are setting favorable probabilities on two drug approvals ahead. Leerink analyst Ami Fadia sounds off from the bulls, maintaining her bet for an FDA win for a drug that could offer this biotech player hundreds of millions in sales.